Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Shepherd

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantationMatthew P Wright, John D Shepherd, Michael J Barnett, et al.
Cancer Genetics and Cytogenetics|September 13, 2006
Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factorsYulia Lin, Hélène Bruyère, Douglas E Horsman, et al.
Leukemia & Lymphoma|July 16, 2005
Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remissionKevin W Song, Peter N Mollee, Donna E Hogge, et al.
British Journal of Haematology|October 4, 2005
Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphomaRichard T Doocey, Cynthia L Toze, Joseph M Connors, et al.
British Journal of Haematology|May 18, 2006
Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphomaKevin W Song, Michael J Barnett, Randy D Gascoyne, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill, John D Shepherd, Heather J Sutherland, et al.
Leukemia Research|September 3, 2008
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levelsDonna L Forrest, Shannon Trainor, Ryan R Brinkman, et al.
Blood|May 5, 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie, Joseph M Connors, Gordon L Phillips, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
British Journal of Haematology|May 30, 2012
Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohortCynthia L Toze, Chinmay B Dalal, Thomas J Nevill, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantationMatthew P Wright, John D Shepherd, Michael J Barnett, et al.
Cancer Genetics and Cytogenetics|September 13, 2006
Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factorsYulia Lin, Hélène Bruyère, Douglas E Horsman, et al.
Leukemia & Lymphoma|July 16, 2005
Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remissionKevin W Song, Peter N Mollee, Donna E Hogge, et al.
British Journal of Haematology|October 4, 2005
Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphomaRichard T Doocey, Cynthia L Toze, Joseph M Connors, et al.
British Journal of Haematology|May 18, 2006
Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphomaKevin W Song, Michael J Barnett, Randy D Gascoyne, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill, John D Shepherd, Heather J Sutherland, et al.
Leukemia Research|September 3, 2008
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levelsDonna L Forrest, Shannon Trainor, Ryan R Brinkman, et al.
Blood|May 5, 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie, Joseph M Connors, Gordon L Phillips, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
British Journal of Haematology|May 30, 2012
Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohortCynthia L Toze, Chinmay B Dalal, Thomas J Nevill, et al.
Pageof 4